Recessive Dystrophic Epidermolysis Bullosa (RDEB) is an inherited genetic skin disorder caused by mutations in the COL7A1 gene encoding type VII collagen (C7). Current therapy is limited to supportive palliation. We report the results of the on going Phase I/IIa clinical trial of ex vivo gene therapy for the treatment of severe RDEB. 6 adult RDEB subjects (mean age 26) enrolled in this trial carried various heterozygous COL7A1 mutations resulting in expression of only truncated C7 protein undetectable by C7 NC2 antibodies and displayed absent/sparse anchoring fibrils (AF) by EM. Autologous RDEB keratinocytes isolated from skin biopsies were transduced with GMP grade retrovirus carrying full-length COL7A1. 6 ~35cm 2 autologous epidermal sheets were grafted onto chronic wounds that were unhealed for a mean of 8.5 years. The primary endpoint of the Phase I/IIA trial is to evaluate wound healing compared to untreated baseline wound. Secondary endpoints included expression of fulllength C7 and restoration of AF at 3 and 6 months. No serious adverse events were reported, and no replication competent virus has been detected for up to 3 years. At 3 months, 94% (27/36 grafts), at 6 months, 67% (16/24 grafts) and at 12 months 50% (12/24 grafts) showed significant wound healing as defined as > 75% healing compared with baseline. C7 expression and morphologically normal NC2 reactive AF were demonstrated at the basement membrane of graft biopsies for up to 2 years however expression gradually diminished over time. These data demonstrate that COL7A1 ex-vivo gene transfer has a favorable safety profile, as well as wound healing efficacy which correlates with molecular correction. Together these findings highlight the potential of cell based therapy in RDEB patients.
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